Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.

On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.

New comprehensive biomarker panels equip physicians with clinically actionable insights for earlier, more accurate diagnosis.

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research.

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.

Aptamer Group plc announces the second phase of its on-going partnership with Neuro-Bio to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease.